Side Effects
Semax has demonstrated a favorable safety profile across both published research and decades of clinical use in Russia. No serious adverse events have been reported in published clinical or preclinical studies.
Commonly Reported:
- Nasal irritation, burning sensation, or mild congestion (localized to the administration route)
- Headache (typically mild, may relate to initial neurotransmitter modulation)
- Sleep disturbance or insomnia (when administered too late in the day)
Less Commonly Reported:
- Transient anxiety or restlessness (more common at higher doses; paradoxical given Semax's general anxiolytic trend)
- Nausea
- Dizziness
- Minor blood pressure fluctuations
Drug Interactions: Semax affects both dopaminergic and serotonergic systems. Combining it with SSRIs, SNRIs, MAOIs, antipsychotics, or stimulant medications could produce amplified or unpredictable effects. No formal interaction studies exist, so co-administration with psychoactive drugs should proceed with caution and medical oversight.
Unstudied Populations: Safety has not been evaluated in pregnancy, lactation, or in patients with significant hepatic or renal impairment. Long-term safety data in healthy populations using research-grade material remains limited.
Sourcing Risks: As with all research peptides obtained outside regulated pharmaceutical supply chains, contamination and purity risks are separate from the compound's intrinsic safety profile. Independent third-party testing is advisable for any research-grade Semax product.